MeiraGTx Holdings plc (NASDAQ:MGTX) CEO Alexandria Forbes sold 4,153 shares of the stock in a transaction that occurred on Wednesday, June 9th. The shares were sold at an average price of $15.04, for a total transaction of $62,461.12. Following the completion of the transaction, the chief executive officer now owns 1,320,781 shares in the company, valued at $19,864,546.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Alexandria Forbes also recently made the following trade(s):
- On Monday, June 7th, Alexandria Forbes sold 5,667 shares of MeiraGTx stock. The shares were sold at an average price of $15.03, for a total transaction of $85,175.01.
Shares of MGTX opened at $14.88 on Friday. The company has a current ratio of 4.30, a quick ratio of 4.30 and a debt-to-equity ratio of 0.09. The business’s 50 day simple moving average is $13.92. MeiraGTx Holdings plc has a 12-month low of $11.35 and a 12-month high of $18.45. The stock has a market capitalization of $658.92 million, a price-to-earnings ratio of -9.02 and a beta of 1.31.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Fort Sheridan Advisors LLC lifted its holdings in shares of MeiraGTx by 13.8% during the fourth quarter. Fort Sheridan Advisors LLC now owns 68,897 shares of the company’s stock worth $1,043,000 after purchasing an additional 8,371 shares during the period. IndexIQ Advisors LLC acquired a new stake in shares of MeiraGTx during the first quarter worth $418,000. ProShare Advisors LLC acquired a new stake in shares of MeiraGTx during the fourth quarter worth $172,000. Trexquant Investment LP acquired a new stake in shares of MeiraGTx during the fourth quarter worth $248,000. Finally, Price T Rowe Associates Inc. MD lifted its holdings in shares of MeiraGTx by 104.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,043,760 shares of the company’s stock worth $30,943,000 after purchasing an additional 1,046,452 shares during the period. 60.20% of the stock is owned by hedge funds and other institutional investors.
MGTX has been the topic of several recent analyst reports. Zacks Investment Research lowered shares of MeiraGTx from a “buy” rating to a “hold” rating in a research note on Wednesday, May 12th. Evercore ISI assumed coverage on shares of MeiraGTx in a research report on Thursday, May 13th. They set a “buy” rating and a $27.00 target price on the stock. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $29.83.
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases.
Receive News & Ratings for MeiraGTx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MeiraGTx and related companies with MarketBeat.com's FREE daily email newsletter.